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Thiazolidinediones: A novel class 
of drugs for the prevention of 
diabetic nephropathy?
F Zheng1 and Y Guan2,3
Diabetic nephropathy is the leading cause of end-stage renal 
disease. Novel preventive measures for diabetic renal complications 
are urgently needed. Miyazaki et al. report that rosiglitazone, 
a thiazolidinedione insulin sensitizer and a potent peroxisome 
proliferator-activated receptor γ agonist, not only effectively 
improves glycemic control but also halts progression of albuminuria 
in type 2 diabetic patients with early-stage diabetic nephropathy. 
These findings could offer a new prevention of diabetic nephropathy 
in insulin-resistant diabetic patients.
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As the prevalence of type 2 diabetes has 
risen to epidemic proportions world-
wide, diabetic renal complications, or 
diabetic nephropathy (DN), has become 
a serious public-health concern.1 The 
population with type 2 diabetes has 
risen about 5% annually in the United 
States since 1990 and shows no sign of 
slowing down. DN is one of the major 
complications of diabetes. About half 
of all diabetic patients have microalbu-
minuria, and among those, about 50% 
eventually develop overt DN. Diabetic 
renal complications in diabetes may 
not only progress to renal failure but 
also significantly increase the risk of 
cardiovascular disease. DN is charac-
terized by sequential pathophysiologi-
cal events including renal hypertrophy, 
extracellular matrix accumulation, and 
renal ﬁbrosis with loss of renal function. 
The pathogenesis of renal involvement 
in diabetes has long been thought to be 
the result of the interplay of metabolic 
and hemodynamic factors. However, it 
has also been noticed that intensive con-
trol of hyperglycemia and hypertension 
eﬀectively prevents or slows its progres-
sion to ESRD in only a subset of diabetic 
patients. Therefore research eﬀorts have 
recently been directed toward prevent-
ing the development and slowing the 
progression of DN.
Among many experimental drugs 
that have been shown to be eﬀective in 
attenuating DN in animal models of type 
2 diabetes, the thiazolidinedione (TZD) 
class of insulin-sensitizing agents holds 
great promise for treating both insulin 
resistance and diabetic renal complica-
tions. TZDs are a group of compounds 
including rosiglitazone (Avandia) and 
pioglitazone (Actos), both widely used 
in diabetes clinic.These agents exert 
their insulin-sensitizing action via 
binding and acting on a nuclear recep-
tor transcription factor designated per-
oxisome proliferator-activated receptor 
γ (PPARγ), which is expressed in many 
insulin-sensitive tissues especially in the 
liver, skeletal muscle, and adipose tis-
sue. Upon activation by TZDs, PPARγ 
modulates gene expression of many 
target genes involved in glucose trans-
port and utilization in peripheral tis-
sues, thereby enhancing insulin action 
and lowering blood glucose.2 Increasing 
evidence in vitro and in animal mod-
els suggests that adipose tissues play 
an important role in these beneficial 
metabolic eﬀects. Activation of adipose 
PPARγ has been shown to improve insu-
lin sensitivity by inhibiting the release 
of free fatty acids (FFAs), tumor necro-
sis factor-α (TNF-α), and resistin, all 
of which have been implicated in the 
pathogenesis of insulin resistance.3 On 
the other hand, TZD treatment has been 
found to attenuate insulin resistance by 
stimulating production of several insu-
lin-sensitizing adipokines, including adi-
ponectin and visfatin. The clinical study 
by Miyazaki et al.4 (this issue) clearly 
demonstrates that 3-month rosiglitazone 
treatment resulted in decreased levels of 
plasma FFAs and TNF-α and increased 
concentrations of adiponectin in type 
2 diabetic patients. This study provides 
important mechanistic insights into 
insulin-sensitizing actions of rosiglita-
zone in this clinical setting and supports 
an idea that pharmacologic interven-
tions aimed at improving lipid toxicity, 
low-grade inﬂammation, and adiponec-
tin may represent novel avenues to treat 
type 2 diabetes.
In addition to metabolic eﬀects, there 
is now a considerable amount of evidence 
suggesting that TZDs can ameliorate 
microalbuminuria and slow the progres-
sion of DN. In type 2 diabetic rodents, 
the TZDs rosiglitazone and pioglitazone 
were found to be eﬀective in the preven-
tion and progression of albuminuria and 
renal ﬁbrosis.5 Consistently, all available 
human studies with TZDs have reported 
a marked reduction in urine albumin-
to-creatinine ratio (UACR) or urinary 
albumin excretion in type 2 diabetes 
with microalbuminuria.6 It appears that 
the favorable renal eﬀect of TZDs in type 
2 diabetes is not completely dependent 
on their insulin-sensitizing action, as 
metformin produced similar glycemic 
control but had practically no eﬀect on 
UACR, as is reported by Miyazaki et al.4 
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and many other groups.6 At present, the 
underlying mechanisms by which TZDs 
exert their renal-protective effects in 
diabetic patients remain only partially 
characterized. In addition to their anti-
hyperglycemic, anti-hyperinsulinemic, 
and anti-hypertensive eﬀects, TZDs may 
also directly act on renal PPARγ in the 
glomeruli and proximal tubules in type 
2 diabetic patients.2 The most intriguing 
and important ﬁnding of the study by 
Miyazaki et al.4 might be that two adi-
pocyte-derived cytokines, TNF-α and 
adiponectin, were diﬀerentially aﬀected 
by rosiglitazone treatment. The authors 
show for the ﬁrst time that reduction in 
the proinﬂammatory adipokine TNF-α 
and increase in anti-inﬂammatory adi-
ponectin were independently associated 
with the regression of UACR in type 2 
diabetic patients after rosiglitazone 
treatment, suggesting that inhibition of 
TNF-α release and stimulation of adi-
ponectin production in adipose tissues 
may represent a novel mechanism con-
tributing to the renal-protective eﬀect of 
TZDs (Figure 1).
To date, it remains only partially under-
stood how TNF-α and adiponectin aﬀect 
renal function in diabetic conditions. 
Although in their discussion Miyazaki et 
al.4 claim that increased circulating TNF-
α was of adipocyte origin, it is also possi-
ble that this cytokine could be produced 
and secreted in diabetic kidneys, where 
TNF-α acts on its receptors to stimulate 
the production of other proinﬂammatory 
factors, recruit inﬂammatory cells, and 
induce cell apoptosis, resulting in renal 
damage. Adiponectin, as an insulin-
sensitizing, anti-inﬂammatory, and vas-
culo-protective cytokine, has been proved 
to ameliorate insulin resistance, low-
grade inﬂammation, and endothelial-
cell dysfunction, which frequently occur 
in type 2 diabetes. Its levels were also 
directly correlated with renal disease pro-
gression.7 The close association between 
plasma adiponectin levels and UACR 
found by Miyazaki and colleagues4 has 
now advanced our understanding of 
this relationship between the adipocyte 
factor adiponectin and albuminuria in 
type 2 diabetic patients. Although the 
mechanisms mediating renoprotec-
tion remain incompletely understood, 
increased adiponectin production by 
TZD treatment may attenuate albuminu-
ria via both systemic (insulin-sensitizing) 
and direct renal action (improving 
endothelium function). This issue war-
rants further investigation.
In the report by Miyazaki and 
colleagues,4 treatment of diabetic patients 
with rosiglitazone, but not with met-
formin, also significantly lowered the 
levels of FFAs in parallel with reduced 
albuminuria. This ﬁnding is important 
and implies that FFA-bounded albumin 
might be ameliorated by TZD treat-
ment. An increasing body of evidence 
has emerged that it is the FFAs bound to 
albumin, rather than albumin itself, that 
cause severe tubulointerstitial damage 
by being reabsorbed into the proximal 
tubule.8 If this is proved true, decreased 
FFA-depleted albuminuria may also con-
tribute to the protective eﬀect of TZDs on 
DN in type 2 diabetic patients (Figure 1).
This study shows that, whereas 
patients treated with placebo had an 
approximately 18% increase in urinary 
albumin excretion, patients receiving 
rosiglitazone treatment exhibited an 
approximately 50% reduction in albu-
minuria. Although the ﬁnding is encour-
aging, one should be cautious in drawing 
a conclusion based on current data, as 
this was a relatively short-term study 
with small samples. Because only 20% of 
type 2 diabetics develop chronic kidney 
disease and DN, usually 10 years after 
the onset of diabetes, it would be essen-
tial to conduct a long-term study with 
a large patient population to determine 
the beneﬁt of TZDs in DN prevention. 
Clinically, the development and progres-
sion of DN occur in several sequential 
stages, including glomerular hyperﬁl-
tration, microalbuminuria (UACR 30–
300 µg/mg), macroalbuminuria (UACR 
>300 µg/mg), and renal failure. It is of 
note that glomerular ﬁltration rate was 
not accurately determined in patients 
in this study. However, data from the 
measurement of creatinine clearance 
appeared to indicate that a few patients 
in both groups might have glomerular 
hyperfiltration. Furthermore, only a 
small proportion of patients seems to 
develop microalbuminuria with a UACR 
greater than 30 µg/mg. Therefore, it 
would be important to revisit the data 
after identifying these patients. Finally, 
a decrease or increase in urine albumin 
excretion within the normal range may 
not be as valuable as we thought in deﬁn-
ing the degree of renal injury or function 
deterioration. Although the study by 
Miyazaki et al.4 was the ﬁrst placebo-
controlled study and provides valuable 
information, a long-term clinical trial 
with a large population is required to 
deﬁne the beneﬁcial role of TZDs in DN 
Figure 1 | Mechanisms by which thiazolidinediones attenuate albuminuria and improve 
diabetic nephropathy. TNF-α, tumor necrosis factor-α; TGFβ, transforming growth factor-β; 
PAI-1, plasminogen activator inhibitor-1; RAS, renin–angiotensin system; ET-1, endothelin-1; 
FFA, free fatty acid; UAE, urinary albumin excretion. Asterisks indicate evidence from the study 
by Miyazaki et al.4
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prevention. It is also worth mentioning 
that rosiglitazone treatment has recently 
been shown to cause severe side eﬀects, 
such as weight gain as seen in this study, 
ﬂuid retention, and increased cardiovas-
cular risk.9,10 Thus, it becomes impor-
tant to determine whether the beneﬁt of 
using TZDs would outweigh the risks.
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Research in HIV-related 
renal diseases lags behind 
their burden to the ‘positive’ 
community
LA Szczech1
Although outcomes for persons with HIV infection and renal disease 
have improved, the analysis by Choi et al. suggests that they remain 
similar to or worse than outcomes for persons with diabetes mellitus. 
This study should be used to frame the research resources that we 
devote to furthering knowledge in this area.
Kidney International (2007) 72, 1303–1305. doi:10.1038/sj.ki.5002562
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It has been my individual perception 
that HIV-related kidney diseases were 
not and are not getting the appropriate 
quantity of dedicated clinical research, 
given the risk of morbidity and mortal-
ity associated with them. I have often 
wondered why.
In the 1980s, when the possibility 
that the HIV virus could be associated 
with the kidney disease HIV-associated 
nephropathy became apparent,1 patient 
outcomes were swift and devastating. 
The average patient was on dialysis 3 
months after the recognition of his or 
her kidney disease,2 and the mortality 
rate was a striking 50% for those who 
survived to dialysis.3–5 I remember the 
problems that we faced with graft infec-
tions among persons with HIV and even 
early discussions of whether or not it 
was appropriate to oﬀer dialysis to this 
group of patients.
The development of eﬀective antiret-
roviral medications was clearly among 
the most amazing and rapid births of 
therapeutic regimens in the history 
of modern medicine. The early 1990s 
brought the availability of eﬀective nucl-
eoside reverse transcriptase inhibitors 
and their now familiar codes of AZT, 
d4T, ddI, and so on. The mid-1990s saw 
the introduction of the ﬁrst protease 
inhibitors. The subsequent development 
of new drug classes—non-nucleoside 
reverse transcriptase inhibitors and 
fusion inhibitors—and the practice of 
combining diﬀerent drug classes into 
exceptionally eﬀective and complemen-
tary regimens (highly active antiretrovi-
ral therapy) have cumulatively improved 
outcomes at an astonishing rate.6 With 
this improvement, it is estimated that 
the relative proportion of persons with 
HIV who begin dialysis has also been 
positively aﬀected.7
So have we won the battle against 
HIV-related renal disease? Absolutely 
not. The article by Choi et al.8 (this 
issue) provides that reality check.
In this analysis of patients receiving 
their care within the Veterans Adminis-
tration Health System, Choi et al.8 dem-
onstrate that the risk of end-stage renal 
disease (ESRD) among African Ameri-
cans is twice as high in those with HIV 
infection as it is in those with diabetes 
mellitus. Given that the rate of decline 
of kidney function and the rate of death 
are also almost twice as high among 
African Americans with HIV infection 
as they are among those with diabetes, 
arguably, it is likely that a signiﬁcant 
proportion of African Americans with 
HIV and chronic kidney disease are 
dying before developing ESRD and that 
the actual risk of ESRD is therefore even 
higher than Choi et al.8 estimate.
